On 24 August, a team of researchers from the Models of Patient Engagement for Alzheimer’s Disease (MOPEAD) project published a scientific article in the journal of Clinical Medicine. In the published paper, scientists focused on a prospective observational study performed only in one center (Vall d’Hebron University Hospital (HVH), Barcelona, Spain). It was previously published that people with Type 2 diabetes (T2D) have more risk of developing Alzheimer’s disease (AD) than the non-diabetic population.
The objectives of this study were to evaluate the results of pre-screening for mild cognitive impairment in people with Type 2 diabetes (T2D) and evaluate the applicability of the Diabetes Specific Dementia Risk Score (DSDRS) as a screening tool for people with T2D and cognitive impairment. A total of 112 T2D research participants were recruited. Authors found a high prevalence of cognitive impairment in TD2 participants older than 65 years old who attended a third-level hospital. In addition, the clinical DSDRS score was found to be a useful screening tool to predict value of cognitive impairment.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations.
